Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2019
2019 World Conference on Lung Cancer
Access to all presentations that occur during the 2019 World Conference on Lung Cancer in Barcelona, Spain
Presentation Date(s):- Sept 7 - 10, 2019
- Total Presentations: 2848
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
P1.13 - Staging
- Type: Poster Viewing in the Exhibit Hall
- Track: Staging
- Presentations: 3
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.13-01 - The Importance of Staging of Lung Cancers, 30 mm or Less, Separately for Subsolid and Solid Nodules
09:45 - 09:45 | Author(s): Yong Wang
- Abstract
Loading... -
+
P1.13-02 - Should Aortic Lymph Nodes be Considered Hilar Lymph Nodes in Patients with Completely Resected NSCLC? A Multicenter Study
09:45 - 09:45 | Presenter: Necati Citak
- Abstract
Loading... -
+
P1.13-03 - Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype
09:45 - 09:45 | Author(s): Ting Ye
- Abstract
Loading... -
+
P1.13-04 - Impact of the Presence and Proportion of GGO on Survival and Pathological Characteristics in Clinical Stage I Lung Adenocarcinoma (Now Available)
09:45 - 09:45 | Presenter: Shinya Katsumata
- Abstract
Loading... -
+
P1.13-05 - Evaluation of PET/CT Scans to Predict Pathologic Lung Cancer Staging (Now Available)
09:45 - 09:45 | Presenter: Mukunthan Murthi
- Abstract
Loading... -
+
P1.13-06 - Impact of Lymph Node Involvement and Tumor Location on Survival Following Resection for pN1/pN2 Non-Small Cell Lung Cancer
09:45 - 09:45 | Author(s): Thomas Tsitsias
- Abstract
Loading... -
+
P1.13-07 - Comparison of the 7th and 8th Edition of TNM Staging for NSCLC in Patients Undergoing Pulmonary Resection After Neoadjuvant/Induction Treatment
09:45 - 09:45 | Presenter: Hüseyin Melek
- Abstract
Loading... -
+
P1.13-08 - The Maximum Standardized Uptake Values on Positron Emission Tomography Predict Pathological Characteristics of Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Terumoto Koike
- Abstract
Loading... -
+
P1.13-09 - Utility of Artificial Intelligence in Estimation of the Histologic Type of Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Yohei Kawaguchi
- Abstract
Loading... -
+
P1.13-10 - Incidence of Hidden Extrathoracic Metastases and Unexpected Second Malignancies Detected by PET in Patients with Lung Cancer
09:45 - 09:45 | Presenter: Bruno García Cabo
- Abstract
Loading... -
+
P1.13-11 - An Audit on IASLC Compliance of Lymph Nodes Dissection and Impact on Survival After Surgery for Non-Small Cell Lung Cancer
09:45 - 09:45 | Author(s): Paulo De Sousa
- Abstract
Loading... -
+
P1.13-12 - The Invasion of Mediastinal Fat Tissue Should be Considered for T4 Description in the Next TNM Classification of NSCLC
09:45 - 09:45 | Presenter: Necati Citak
- Abstract
Loading... -
+
P1.13-13 - High-Risk Clinical Stage I Non-Small Cell Lung Cancer Based on High-Resolution Computed Tomography Findings
09:45 - 09:45 | Presenter: Yasuhiro Tsutani
- Abstract
Loading... -
+
P1.13-14 - Prognosis and Clinicopathologic Characteristics of Skip N2 Metastasis in Completely Resected Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Takaaki Tsuboi
- Abstract
Loading...
-
+
P1.14 - Targeted Therapy
- Type: Poster Viewing in the Exhibit Hall
- Track: Targeted Therapy
- Presentations: 15
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.14-01 - Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?
09:45 - 09:45 | Presenter: Omer Fatih Olmez
- Abstract
Loading... -
+
P1.14-02 - Survey of EGFR Molecular Testing of NSCLC in the Asia-Pacific Region
09:45 - 09:45 | Presenter: Chong Kin Liam
- Abstract
Loading... -
+
P1.14-03 - Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial
09:45 - 09:45 | Presenter: Lorenza Landi
- Abstract
Loading... -
+
P1.14-04 - Final Results of the Prospective Genomics of Young Lung Cancer (GYLC), an Addario Lung Cancer Medical Institute Study
09:45 - 09:45 | Presenter: Barbara Gitlitz
- Abstract
Loading... -
+
P1.14-05 - TP53 Exon 8 Mutation and Prognosis in EGFR-Mutated NSCLC Patients Treated with First-And-Second-Generation TKIs
09:45 - 09:45 | Author(s): Matteo Canale
- Abstract
Loading... -
+
P1.14-06 - Tissue-Based Molecular and Histologic Landscape of Acquired Resistance to Osimertinib in Patients with EGFR-Mutant Lung Cancers
09:45 - 09:45 | Presenter: Adam J Schoenfeld
- Abstract
Loading... -
+
P1.14-07 - Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance
09:45 - 09:45 | Presenter: Erin L Stewart
- Abstract
Loading... -
+
P1.14-08 - Activity of Poziotinib and Other 2nd-Gen Quinazoline EGFR TKIs in Atypical Exon18 and Acquired Osimertinib Resistance Mutants
09:45 - 09:45 | Presenter: Jacqulyne Ponville Robichaux
- Abstract
Loading... -
+
P1.14-09 - Unveiling Hidden MET-Mediated Primary Alectinib Resistance in ALK-Positive Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Anh Tuan Le
- Abstract
Loading... -
+
P1.14-10 - The Landscape of RET Genomic Alterations in Chinese Non-Small Cell Lung Cancer Patients
09:45 - 09:45 | Author(s): Xiangyan Liu
- Abstract
Loading... -
+
P1.14-11 - A Prospective Multicenter Study of Target-Capture Deep Sequencing in Paired Tissue and ctDNA to Guide EGFR-Mutated Lung Cancer Treatment (Now Available)
09:45 - 09:45 | Presenter: Shun Lu
- Abstract
Loading... -
+
P1.14-12 - A Novel Activating MAP2K1 In-Frame Deletion Mediates Acquired Resistance to ROS1 TKIs in a Patient with ROS1 Fusion-Positive NSCLC
09:45 - 09:45 | Presenter: Hiroki Sato
- Abstract
Loading... -
+
P1.14-13 - EGFR Amplification Mediates Resistance to Third-Generation EGFR TKIs and in Vitro Validation of Combination Strategies to Overcome Resistance (Now Available)
09:45 - 09:45 | Presenter: Yi-Chen Zhang
- Abstract
Loading... -
+
P1.14-14 - Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC (Now Available)
09:45 - 09:45 | Presenter: Katja Mohorcic
- Abstract
Loading... -
+
P1.14-15 - Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
09:45 - 09:45 | Author(s): Saadettin Kilickap
- Abstract
Loading... -
+
P1.14-16 - Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
09:45 - 09:45 | Presenter: Xue Yang
- Abstract
Loading... -
+
P1.14-17 - Genomic Evolution During TKI Treatment in Non-Small Cell Lung Cancer Patients With or Without Acquired T790M Mutation
09:45 - 09:45 | Author(s): Ying Jin
- Abstract
Loading... -
+
P1.14-18 - ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK+) NSCLC Patients in the US Community Oncology Setting
09:45 - 09:45 | Author(s): David M Waterhouse
- Abstract
Loading... -
+
P1.14-19 - Exome Analysis of Patients Treated with Afatinib Reveals Genetic Variations Discriminating Extreme Responders (Now Available)
09:45 - 09:45 | Presenter: Julie Niogret
- Abstract
Loading... -
+
P1.14-20 - Tarloxotinib as a Novel Therapeutic Strategy for Oncogenic Alterations Across the ErbB Family of Receptors
09:45 - 09:45 | Presenter: Adriana Estrada-Bernal
- Abstract
Loading... -
+
P1.14-21 - Propensity-Matched Genomic Profiling Comparison of Lung Adenocarcinomas Among 3 Races, a Multicenter Study of 4655 Patients
09:45 - 09:45 | Presenter: Ke Lan
- Abstract
Loading... -
+
P1.14-22 - SASH1, a Novel Prognostic and Predictive Factor for PARP Inhibitors in Lung Cancer
09:45 - 09:45 | Presenter: Joshua Burgess
- Abstract
Loading... -
+
P1.14-23 - Resistance Mechanisms to Osimertinib Treatment in EGFR-Mutated Lung Cancer in a Real Life Cohort (Now Available)
09:45 - 09:45 | Presenter: Christi M.J. Steendam
- Abstract
Loading... -
+
P1.14-24 - Characterization of Acquired Receptor Tyrosine Kinase Fusions as Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors (Now Available)
09:45 - 09:45 | Presenter: Haiyuan Xu
- Abstract
Loading... -
+
P1.14-25 - Targeting NRG1-Fusions in Lung Adenocarcinoma: Afatinib as a Novel Potential Treatment Strategy
09:45 - 09:45 | Presenter: Michael Duruisseaux
- Abstract
Loading... -
+
P1.14-26 - ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma
09:45 - 09:45 | Presenter: Fabrizio Tabbò
- Abstract
Loading... -
+
P1.14-27 - Duration of Targeted Therapy in Advanced NSCLC (aNSCLC) with Drivers Identified by Circulating Tumor DNA (ctDNA) Analysis
09:45 - 09:45 | Presenter: Christina Baik
- Abstract
Loading... -
+
P1.14-28 - Correlation Between the Qualification for the Bevacizumab Use and the Survival of NSCLC Patients with EGFR Mutations
09:45 - 09:45 | Presenter: Taiki Hakozaki
- Abstract
Loading... -
+
P1.14-29 - Disrupting the Paradigm: Partnering with Oncogene-Focused Patient Groups to Propel Research
09:45 - 09:45 | Presenter: Janet Freeman-Daily
- Abstract
Loading... -
+
P1.14-30 - Phase I Study of Afatinib Plus Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
09:45 - 09:45 | Presenter: Takaaki Tokito
- Abstract
Loading... -
+
P1.14-31 - Lack of Association Between BIM Deletion Polymorphism and Clinical Efficacy of EGFR-TKIs in NSCLC Based on NGS (Now Available)
09:45 - 09:45 | Presenter: Si-Yang Liu
- Abstract
Loading... -
+
P1.14-32 - Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
09:45 - 09:45 | Presenter: Heather A Wakelee
- Abstract
Loading... -
+
P1.14-33 - Canagliflozin Inhibits Lung Cancer Survival and Enhances Its Response to Radiotherapy; Effective Blockade of mTOR Pathway, HIF1a, and Mitosis
09:45 - 09:45 | Presenter: Evangelia Evelyn Tsakiridis
- Abstract
Loading... -
+
P1.14-34 - The Landscape of MET Alterations in Chinese Non-Small Cell Lung Cancer Patients
09:45 - 09:45 | Author(s): Min Zheng
- Abstract
Loading... -
+
P1.14-35 - Epithelial-To-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
09:45 - 09:45 | Presenter: Koji Fukuda
- Abstract
Loading... -
+
P1.14-36 - Phase II Trial of Afatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Ryo Ko
- Abstract
Loading... -
+
P1.14-37 - Lung Cancer in Never-Smokers: A Nationwide Population Based Mapping of Targetable Alterations
09:45 - 09:45 | Author(s): Annette Salomonsson
- Abstract
Loading... -
+
P1.14-38 - Identification of FGFR1-3 Fusions in Lung Cancers Using Comprehensive Next-Generation Sequencing (Now Available)
09:45 - 09:45 | Presenter: Gen Lin
- Abstract
Loading... -
+
P1.14-39 - Acquired ALK Rearrangement in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR TKIs
09:45 - 09:45 | Presenter: Qian-Yu Wang
- Abstract
Loading... -
+
P1.14-40 - EGFR-TKIs May Sensitize Radiation Lung Damage in Stereotactic Body Radiotherapy Based on Intensity Analyzing
09:45 - 09:45 | Presenter: Xingni Tang
- Abstract
Loading... -
+
P1.14-41 - The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells
09:45 - 09:45 | Presenter: Nicholas Jette
- Abstract
Loading... -
+
P1.14-42 - Apatinib Combined with EGFR - TKI in Treating Advanced Non-Small Cell Lung Cancer with EGFR - TKI Resistance (Data Updated)
09:45 - 09:45 | Presenter: Ruifen Tian
- Abstract
Loading... -
+
P1.14-43 - A Novel Patient Derived Synchronous Cell Pair with Different Mutations in an ALK-Rearranged Lung Adenocarcinoma Underlines Tumor Heterogeneity
09:45 - 09:45 | Presenter: Paul Stockhammer
- Abstract
Loading... -
+
P1.14-44 - Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
09:45 - 09:45 | Author(s): Seung Hyeun Lee
- Abstract
Loading... -
+
P1.14-45 - Surgical Outcome of Non-Small Cell Lung Cancer with Clinical Single Zone N2 in Aortopulmonary Zone (LN#5 and LN#6) (Now Available)
09:45 - 09:45 | Presenter: Kanghoon Lee
- Abstract
Loading... -
+
P1.14-46 - Genomic Profiling of Large Cell Neuroendocrine Carcinomas of Lung: A Path Towards Individualized Treatment Options
09:45 - 09:45 | Presenter: Nhu Thi Ngo
- Abstract
Loading... -
+
P1.14-47 - ctDNA NGS for Guiding Crizotinib Treatment in ALK-Rearranged Advanced NSCLC Patients (Pts) (Now Available)
09:45 - 09:45 | Presenter: Yong He
- Abstract
Loading... -
+
P1.14-48 - Whole Exome Sequencing (WES) in Non-Small Cell Lung Carcinoma (NSCLC): Identification of Novel Biomarkers (Now Available)
09:45 - 09:45 | Presenter: Varsha Singh
- Abstract
Loading... -
+
P1.14-49 - The Role of ctDNA Detection (Liquid Biopsy) in Patients with NSСLC
09:45 - 09:45 | Presenter: Albina Zhabina
- Abstract
Loading... -
+
P1.14-50 - A Phase 2 Trial of Cabozantinib in ROS1-Rearranged Lung Adenocarcinoma (Now Available)
09:45 - 09:45 | Presenter: Robin Guo
- Abstract
Loading... -
+
P1.14-51 - LOC440416 lncRNA-Mediated Cell Cycle Arrest Regulated Crizotinib-Induced Hepatotoxicity
09:45 - 09:45 | Presenter: Xueqin Chen
- Abstract
Loading... -
+
P1.14-52 - Clinical Response to Osimertinib in a Patient with Metastatic NSCLC Harboring EGFR A763_Y764insFQEA Exon 20 Insertion Mutation: A Case Report (Now Available)
09:45 - 09:45 | Presenter: Gabriela Liliana Bravo Montenegro
- Abstract
Loading... -
+
P1.14-53 - Co-Occurring CDKN2A/2B Alteration Is Associated with Poorer Survival in ALK-Positive Lung Cancer
09:45 - 09:45 | Presenter: Joo Young Ha
- Abstract
Loading... -
+
P1.14-54 - Previous Therapy Strategy Impact on Efficiency of Anlotinib Hydrochloride as 3rd Line Treatment: A Subgroup Analysis of ALTER0303 Trial (Now Available)
09:45 - 09:45 | Presenter: Sen Yang
- Abstract
Loading... -
+
P1.14-55 - Cost-Effectiveness of Ceritinib and Alectinib vs Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced NSCLC
09:45 - 09:45 | Presenter: Bin Wu
- Abstract
Loading... -
+
P1.14-56 - The Dynamic Range of Mutant Allele Fraction Detected in ctDNA from Patients with NSCLC: Clinical Experience Data and Clinical Implications
09:45 - 09:45 | Author(s): Smitha Boorgula
- Abstract
Loading... -
+
P1.14-57 - Post-Ensartinib Outcomes in Refractory Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
09:45 - 09:45 | Author(s): Hans Kim
- Abstract
Loading... -
+
P1.14-58 - A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
09:45 - 09:45 | Author(s): Julia Rotow
- Abstract
Loading... -
+
P1.14-59 - Clinical Implications of the Pharmacokinetics of Dacomitinib Co-Administration with H2-Receptor Antagonists in Cancer Patients
09:45 - 09:45 | Presenter: Swan Lin
- Abstract
Loading... -
+
P1.14-60 - Statins Overcome Resistance to Tyrosine Kinase Inhibitors in Patient-Derived, Oncogene-Driven NSCLC Models
09:45 - 09:45 | Presenter: Weijie Ma
- Abstract
Loading... -
+
P1.14-61 - EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR+ NSCLC Patients with BIM Deletions
09:45 - 09:45 | Author(s): Andrés Felipe Cardona
- Abstract
Loading... -
+
P1.14-62 - Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Combined Analysis of Two Single-Arm Phase IIIb Studies
09:45 - 09:45 | Author(s): Filippo De Marinis
- Abstract
Loading...
-
+
P1.15 - Thymoma/Other Thoracic Malignancies
- Type: Poster Viewing in the Exhibit Hall
- Track: Thymoma/Other Thoracic Malignancies
- Presentations: 8
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.15-01 - Prognostic Factors and Long-Term Outcomes After Pulmonary Metastasectomy from Renal Cell Carcinoma (Now Available)
09:45 - 09:45 | Presenter: Domenico Galetta
- Abstract
Loading... -
+
P1.15-02 - Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
09:45 - 09:45 | Presenter: Jessica Hellyer
- Abstract
Loading... -
+
P1.15-03 - Cabozantinib and R428 Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
09:45 - 09:45 | Presenter: Pei-Wen Yang
- Abstract
Loading... -
+
P1.15-04 - Multimodality Treatment of Chest Wall Tumors: Induction Therapy Reduces Recurrence Rates (Now Available)
09:45 - 09:45 | Presenter: Milos Sarvan
- Abstract
Loading... -
+
P1.15-05 - Genomic Variation Landscape of Thymoma and Thymic Carcinoma in Chinese Patients (Now Available)
09:45 - 09:45 | Presenter: Naixin 13701089919 Liang
- Abstract
Loading... -
+
P1.15-06 - Resection of Thoracic Paragangliomas: A Multicenter Experience (Now Available)
09:45 - 09:45 | Author(s): Sergio Ibarra
- Abstract
Loading... -
+
P1.15-07 - Combined Aortic Arch Resection for Thymic Cancer Using Total Rerouting of Supra-Arch Vessels
09:45 - 09:45 | Presenter: Yasushi Shintani
- Abstract
Loading... -
+
P1.15-08 - Outcomes of T4 Esophageal Cancer Treated with Neoadjuvant Chemoradiation Followed by Surgery and Definitive Chemoradiation: A Meta-Analysis
09:45 - 09:45 | Presenter: Chia Ching Lee
- Abstract
Loading... -
+
P1.15-09 - The Impact of Minimal Invasive Esophagectomy and Neoadjuvant Chemoradiotherapy for Esophageal Malignancy: A Nationwide Database Analysis
09:45 - 09:45 | Presenter: Cheng-Hung How
- Abstract
Loading... -
+
P1.15-10 - Trabectedin Has Limited Clinical Activity in Pretreated Patients with Pleural Mesothelioma (Now Available)
09:45 - 09:45 | Author(s): Giulia Pasquini
- Abstract
Loading... -
+
P1.15-11 - Intrathoracic Neurogenic Tumors: Clinical, Pathological, and Long-Term Outcomes (Now Available)
09:45 - 09:45 | Presenter: Domenico Galetta
- Abstract
Loading... -
+
P1.15-12 - A Different Aspect to Tumor Size Dilemma in Thymoma's TNM Staging Classification (Now Available)
09:45 - 09:45 | Author(s): Ayten Kayi Cangir
- Abstract
Loading... -
+
P1.15-13 - Subxiphoid Uniportal Thoracoscopic Thymectomy Without Carbon Dioxide Insufflation in the Patients with Thymoma (Now Available)
09:45 - 09:45 | Presenter: Do Kyun Kang
- Abstract
Loading...
-
+
P1.16 - Treatment in the Real World - Support, Survivorship, Systems Research
- Type: Poster Viewing in the Exhibit Hall
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
- Presentations: 17
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.16-01 - Complications Associated with Lung Biopsies in Patients with Lung Cancer: A Population Based Analysis
09:45 - 09:45 | Author(s): Mitchell Von Itzstein
- Abstract
Loading... -
+
P1.16-02 - The Real-World Risk of Brain Metastases in Stage 3 Lung Cancer Patients in the Era of PET and MRI Staging (Now Available)
09:45 - 09:45 | Author(s): Ryan Brendan Ko
- Abstract
Loading... -
+
P1.16-03 - Incidence and Risk Factors of Metachronous Non-Pulmonary Malignancies in Resected Lung Adenocarcinoma
09:45 - 09:45 | Presenter: Peter J Kneuertz
- Abstract
Loading... -
+
P1.16-04 - Real World Experience of Using Comprehensive Genomic Profiling of Plasma Circulating Tumor DNA
09:45 - 09:45 | Presenter: Yan Yan
- Abstract
Loading... -
+
P1.16-05 - Incidence and Outcome of Multiple Primary Cancers (MPC) in a Series of Lung Cancer (LC) Patients
09:45 - 09:45 | Presenter: Susana Cedres
- Abstract
Loading... -
+
P1.16-06 - Early Changes in Pulmonary Function Are Associated with Development of Pneumonitis in NSCLC Patients Receiving Immune Checkpoint Blockade
09:45 - 09:45 | Presenter: Joshua Reuss
- Abstract
Loading... -
+
P1.16-07 - Real World Evidence of the Impact of Immunotherapy in Patients with Advanced Lung Cancer (Now Available)
09:45 - 09:45 | Author(s): Christopher Pettengell
- Abstract
Loading... -
+
P1.16-08 - Integration of Durvalumab into the Treatment of Stage III Non-Small Cell Lung Cancer: Real-World Considerations
09:45 - 09:45 | Presenter: Sophia Valesca Gorgens
- Abstract
Loading... -
+
P1.16-09 - Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort
09:45 - 09:45 | Author(s): Giulio Metro
- Abstract
Loading... -
+
P1.16-10 - Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina (Now Available)
09:45 - 09:45 | Author(s): Alejandro Daniel Kuzminin
- Abstract
Loading... -
+
P1.16-11 - A Dyad-Based Mindfulness Cancer Recovery Program for Survivors and Family Members to Reduce Lung Cancer Symptoms (Now Available)
09:45 - 09:45 | Presenter: Karen Kane McDonnell
- Abstract
Loading... -
+
P1.16-12 - An Analysis of Healthcare Use and the Cost Associated to End-of-Life Care of Lung Cancer Patients in a Spanish Hospital (Now Available)
09:45 - 09:45 | Author(s): Juan Luis Cruz
- Abstract
Loading... -
+
P1.16-13 - Development of a Veterans Affairs Based Comprehensive Lung Cancer Survivorship Program
09:45 - 09:45 | Presenter: Scott Shofer
- Abstract
Loading... -
+
P1.16-14 - Effects of an Artificial Intelligence (AI) System on Clinical Trial Enrollment in Lung Cancer
09:45 - 09:45 | Presenter: Konstantinos Leventakos
- Abstract
Loading... -
+
P1.16-15 - Rates of Systemic Anticancer Therapy (SACT) for Advanced Non-Small Cell Lung Cancer (aNSCLC) in the US, 2011–2018
09:45 - 09:45 | Presenter: Vamsidhar Velcheti
- Abstract
Loading... -
+
P1.16-16 - Lung Cancer Control in Sub-Saharan Africa: Experience at Ampath Oncology in Western Kenya (Now Available)
09:45 - 09:45 | Presenter: Fredrick Chite Asirwa
- Abstract
Loading... -
+
P1.16-17 - Getting to Know Our Weapons Better. Analyze from Real Life Data from León, Spain (Now Available)
09:45 - 09:45 | Presenter: Luis Felipe Sánchez-Cousido
- Abstract
Loading... -
+
P1.16-18 - Pleural Malignant Effusion. Is it Possible to Predict Recurrence After Palliative Pleural Procedure?
09:45 - 09:45 | Presenter: Fernando Conrado Abrao
- Abstract
Loading... -
+
P1.16-19 - Understanding Physician Barriers in the Management of Lung Cancer in Nepal. Can Educational Intervention Make a Difference? (Now Available)
09:45 - 09:45 | Presenter: Ramila Shilpakar
- Abstract
Loading... -
+
P1.16-20 - Trial in Progress: Cardiac Toxicity in Patients Undergoing Curative Intent Radiotherapy for Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Kathryn Elizabeth Banfill
- Abstract
Loading... -
+
P1.16-21 - Does Age Affect What Patients Value When Considering Lung Cancer Treatments? Evidence from a National Survey
09:45 - 09:45 | Author(s): Carolyn J Presley
- Abstract
Loading... -
+
P1.16-22 - Reduced Delays in Diagnostic Pathways for Non-Small Cell Lung Cancer After Local and National Interventions (Now Available)
09:45 - 09:45 | Presenter: Dan Lærum
- Abstract
Loading... -
+
P1.16-23 - Comparison of Electronic and Traditional Thoracic Drainage Systems for Postoperative Chest Tube Management After Pulmonary Resection
09:45 - 09:45 | Presenter: Ching Feng Wu
- Abstract
Loading... -
+
P1.16-24 - Detection of Plasma T790M Mutation After the First Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer in the Real World (Now Available)
09:45 - 09:45 | Presenter: Haiyan Li
- Abstract
Loading... -
+
P1.16-25 - Impact of Pirfenidone on the Risk Scoring System of Postoperative Acute Exacerbation of Interstitial Pneumonia in Lung Cancer
09:45 - 09:45 | Presenter: Ryohei Matsushima
- Abstract
Loading... -
+
P1.16-26 - Epithelial Growth Factor Receptor Mutation Pattern in Non-Small Cell Lung Cancer of Xuanwei Region in Southwestern China (Now Available)
09:45 - 09:45 | Author(s): Li Lv
- Abstract
Loading... -
+
P1.16-27 - Risk Factors Associated with a Second Primary Lung Cancer (SPLC) in Patients (Pts) with an Initial Primary Lung Cancer (IPLC)
09:45 - 09:45 | Presenter: Misako Nagasaka
- Abstract
Loading... -
+
P1.16-28 - The Humanistic Burden of ALK+ NSCLC: Findings from the ALKConnect Patient Insight Network and Research Platform
09:45 - 09:45 | Presenter: Huamao Mark Lin
- Abstract
Loading... -
+
P1.16-29 - Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yukihiro Toi
- Abstract
Loading... -
+
P1.16-30 - Impact of Patient TKI Copayments on Insurance Expenditure in Advanced EGFR or ALK Positive Non-Small Cell Lung Cancer (NSCLC)
09:45 - 09:45 | Presenter: Bernardo Haddock Lobo Goulart
- Abstract
Loading... -
+
P1.16-31 - Body Mass Index Relating to Patient-Reported Symptoms in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
09:45 - 09:45 | Author(s): Qiuling Shi
- Abstract
Loading... -
+
P1.16-32 - Empowering Lung Cancer Survivors and Family Members to “Breathe Easier”: Adaptation and Evaluation of a M-Health Intervention (Now Available)
09:45 - 09:45 | Presenter: Otis LeShaun Owens
- Abstract
Loading... -
+
P1.16-33 - From a Systematic Review to Real World Evidence: Integrating Gender as a Clinical Risk Factor in NSCLC
09:45 - 09:45 | Author(s): Noor Asaad Alsaadoun
- Abstract
Loading... -
+
P1.16-34 - Association Between Skin Reactions and Clinical Benefit in Patients Treated with Anti-PD-1 Treatment for Advanced Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Mari Aso
- Abstract
Loading... -
+
P1.16-35 - The Prognostic Impact of Sarcopenia on the Clinical Outcome of Thoracic Surgery for Non-Small Cell Lung Cancer in Elderly Patients
09:45 - 09:45 | Presenter: Akihiro Miura
- Abstract
Loading... -
+
P1.16-36 - Treatment Patterns Among Patients with EGFRm NSCLC Treated in the US Community Oncology Setting
09:45 - 09:45 | Presenter: Melissa Pavilack
- Abstract
Loading... -
+
P1.16-37 - Correlation Between the Actual Measurement Value After Lung Lobectomy and the Predicted Value of Forced Expiratory Volume in 1 Second (Now Available)
09:45 - 09:45 | Presenter: Tatsuya Hayashi
- Abstract
Loading... -
+
P1.16-38 - Racial Disparities in Long-Term Survival After Surgical Resection in the US (Now Available)
09:45 - 09:45 | Presenter: Meghan Taylor
- Abstract
Loading... -
+
P1.16-39 - Oncology Emergencies in Patients with Lung Cancer: Experience of One Hospital (Now Available)
09:45 - 09:45 | Presenter: Marta Vilaça
- Abstract
Loading... -
+
P1.16-40 - Real-World Neurocognitive Function in Lung Cancer: Initial Results of the PRO-Long Study
09:45 - 09:45 | Presenter: Lotte Anna Van Der Weijst
- Abstract
Loading... -
+
P1.16-41 - Timing, Sites, and Correlates of Lung Cancer Recurrence: The Missing Pieces in National Datasets
09:45 - 09:45 | Author(s): Chelsea M Karacz
- Abstract
Loading... -
+
P1.16-42 - Real-World Trends in Systemic Anticancer Therapy (SACT) for Squamous Advanced NSCLC (aNSCLC) in the US, 2011–2018
09:45 - 09:45 | Presenter: Vamsidhar Velcheti
- Abstract
Loading... -
+
P1.16-43 - Prevalence of Clinical and Sub-Clinical Malnutrition in Advanced Non-Small-Cell Lung Cancer Patients and Association with Outcome
09:45 - 09:45 | Author(s): Ilaria Trestini
- Abstract
Loading... -
+
P1.16-44 - Multiple Primary Cancers (MPC) in a Cohort of Lung Cancer (LC) Patients (P): Incidence and Clinical Features
09:45 - 09:45 | Presenter: Carlos Erasun Lecuona
- Abstract
Loading... -
+
P1.16-45 - Changing Attitudes Regarding Lung Cancer: Shame, Embarrassment, and Hope
09:45 - 09:45 | Presenter: Joan H Schiller
- Abstract
Loading... -
+
P1.16-46 - Genetic Testing Patterns, Treatment Characteristics, and Overall Survival in ALK-Positive Metastatic NSCLC Patients Treated with Ceritinib
09:45 - 09:45 | Presenter: Julien Mazieres
- Abstract
Loading... -
+
P1.16-47 - Embedding Research (and Evidence) in Cancer Healthcare - EnRICH
09:45 - 09:45 | Presenter: Bea Brown
- Abstract
Loading... -
+
P1.16-48 - Experiences of Pts on 1st Line Care (EP1C): Symptoms and Impacts of EGFR TKI Therapy on Real-World Daily Lives of NSCLC Pts
09:45 - 09:45 | Presenter: Ivy Elkins
- Abstract
Loading...
-
+
P1.17 - Treatment of Early Stage/Localized Disease
- Type: Poster Viewing in the Exhibit Hall
- Track: Treatment of Early Stage/Localized Disease
- Presentations: 17
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.17-01 - Surgical Outcome of Early Stage Lung Cancer Related vs Unrelated to Honeycomb Lesions with Interstitial Pneumonia (Now Available)
09:45 - 09:45 | Presenter: Makoto Fujiwara
- Abstract
Loading... -
+
P1.17-02 - The Investigation of Intraoperative Marking by Transbronchial Low Power Laser Irradiation in Human Lung
09:45 - 09:45 | Presenter: Keishi Ohtani
- Abstract
Loading... -
+
P1.17-03 - Inter-Fraction Variability of 18-FDG PET During Lung SBRT and the Effect of Systemic and Immunotherapy: Results of a Prospective Pilot Study (Now Available)
09:45 - 09:45 | Presenter: Sibo Tian
- Abstract
Loading... -
+
P1.17-04 - Multicenter Observational Study of Node-Negative Non-Small Cell Lung Cancer Patients Who Are Excluded from a Clinical Trial
09:45 - 09:45 | Presenter: Hiroyuki Sakurai
- Abstract
Loading... -
+
P1.17-05 - What Is the Optimal Number of Examined Lymph Node in Stage IA Non-Small Cell Lung Cancer?
09:45 - 09:45 | Author(s): Liu Huang
- Abstract
Loading... -
+
P1.17-06 - Long-Term Oncological Outcome After Thoracoscopic Lobectomy for Non-Small Cell Lung Cancer Patients (Now Available)
09:45 - 09:45 | Presenter: Masayuki Nakao
- Abstract
Loading... -
+
P1.17-07 - Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study
09:45 - 09:45 | Presenter: Aaron C Tan
- Abstract
Loading... -
+
P1.17-08 - mRNA Expression Level of Receptor Tyrosine Kinases and Non-Receptor Tyrosine Kinases as a Recurrence Risk in Resected Adenocarcinoma of the Lung
09:45 - 09:45 | Presenter: Masaoki Ito
- Abstract
Loading... -
+
P1.17-09 - Surgical Outcomes of Complex Versus Simple Segmentectomy for Stage I Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yoshinori Handa
- Abstract
Loading... -
+
P1.17-10 - Prediction of Visceral Pleural Invasion in c-N0 Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Satoru Okada
- Abstract
Loading... -
+
P1.17-11 - Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early Stage Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Corbin D Jacobs
- Abstract
Loading... -
+
P1.17-12 - Osteogenic and Brain Metastases After Resection of NSCLC: Implications for the Use of FDG-PET and Brain MRI in Postoperative Surveillance (Now Available)
09:45 - 09:45 | Presenter: Tetsuya Mizuno
- Abstract
Loading... -
+
P1.17-13 - Next Generation Sequencing of the Circulating Small RNA from Serum Identifies Small RNA-Based Biomarker Panel for Stage I-II Lung Adenocarcinoma
09:45 - 09:45 | Presenter: Daisuke Ueda
- Abstract
Loading... -
+
P1.17-14 - Prognostic Value of Immune Cell Biomarkers in Surgically Resectable Non-Small Cell Lung Cancer: A Meta-Analysis (Now Available)
09:45 - 09:45 | Presenter: Stephanie Tuminello
- Abstract
Loading... -
+
P1.17-15 - Risk, Pattern and Outcome of Brain Metastases in Completely Resected Stage I (AJCC 8th Edition) Non-Squamous Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Jianjiao Ni
- Abstract
Loading... -
+
P1.17-16 - Neo-Adjuvant Targeted Therapy in Non-Small Cell Lung Cancer Patients: A 10-Year Experience in a Tertiary Medical Center
09:45 - 09:45 | Presenter: Hsu Ching Huang
- Abstract
Loading... -
+
P1.17-17 - Outcomes Following Stereotactic Body Radiotherapy (SBRT) for Biopsy-Confirmed vs. Radiologically-Diagnosed Primary Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Tze Lui Koh
- Abstract
Loading... -
+
P1.17-18 - Surgery Alone or Plus Adjuvant Radiotherapy for Patients with N0 Non-Small-Cell Lung Cancer >5 cm: A Population-Based Study (Now Available)
09:45 - 09:45 | Presenter: Junmiao Wen
- Abstract
Loading... -
+
P1.17-19 - Lobe-Specific Lymph Node Dissection for Clinical Early-Stage (cIA) Peripheral Non-Small Cell Lung Cancer Patients: Feasible and How?
09:45 - 09:45 | Presenter: Han-Yu Deng
- Abstract
Loading... -
+
P1.17-20 - Evaluation of Efficacy and Safety of Uniportal Segmentectomy in the Treatment of Lung Cancer
09:45 - 09:45 | Presenter: Chenlei Zhang
- Abstract
Loading... -
+
P1.17-21 - Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review (Now Available)
09:45 - 09:45 | Presenter: Hanbo Chen
- Abstract
Loading... -
+
P1.17-22 - Do Statins Improve Outcomes After Radical Radiotherapy for Lung Cancer? An In-Depth Analysis of Over 1100 Patients (Now Available)
09:45 - 09:45 | Presenter: Fei Sun
- Abstract
Loading... -
+
P1.17-23 - Outcome After Surgical Resection for Clinical Stage I Non-Small Cell Lung Cancer Associated with Interstitial Lung Disease (Now Available)
09:45 - 09:45 | Presenter: Takahisa Koizumi
- Abstract
Loading... -
+
P1.17-24 - Treatment of Ultracentral Lung Tumors with Hypofractionated Radiation Therapy
09:45 - 09:45 | Presenter: Tamara Nsouli
- Abstract
Loading... -
+
P1.17-25 - Outcomes of Primary Lung Cancer SBRT in Patients with Compromised Lung Function
09:45 - 09:45 | Presenter: Elaine Kirby
- Abstract
Loading... -
+
P1.17-26 - Delivery of Stereotactic MR-Guided Adaptive Radiation Therapy for Peripheral Lung Tumors
09:45 - 09:45 | Presenter: Tobias Finazzi
- Abstract
Loading... -
+
P1.17-27 - Stereotactic Radiotherapy for Primary Lung Tumors: The Influence of Size
09:45 - 09:45 | Presenter: Isabel Rodrigues
- Abstract
Loading... -
+
P1.17-28 - Refusal of Surgery for Early Stage Lung Cancer: Risk Factors and Survival
09:45 - 09:45 | Author(s): Joseph Rapp
- Abstract
Loading... -
+
P1.17-29 - 8-year Experience of Navigational Bronchoscopy for Preoperative Localization of Subcentimeter Lung Nodules in a Small Community Hospital
09:45 - 09:45 | Author(s): Christian Rodolfo Galvez-Padilla
- Abstract
Loading... -
+
P1.17-30 - Sex and Age-Associated Survival Following Resected Early Stage Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading... -
+
P1.17-31 - VATS Segmentectomies Are at Least as Safe as VATS Lobectomies (Now Available)
09:45 - 09:45 | Presenter: Tomasz Marjanski
- Abstract
Loading... -
+
P1.17-32 - The 8th Editions of the AJCC Staging System in Terms of Predicting Recurrence and Survival in Resected NSCLC Long-Term Survivors (Now Available)
09:45 - 09:45 | Presenter: Seung Hwan Song
- Abstract
Loading... -
+
P1.17-34 - Prognostic Significance of Preoperative CT-Determined Sarcopenia and Radiodensity in Resected Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Eun Young Kim
- Abstract
Loading... -
+
P1.17-35 - Solid Predominant Subtype Is an Independent Risk Factor for Recurrence in Patients with Pathologic Stage I Adenocarcinoma
09:45 - 09:45 | Presenter: Kisung Park
- Abstract
Loading... -
+
P1.17-36 - Analyses of Segmental and Intrapulmonary Lymph Node Metastases of Small-Sized Peripheral Solid Predominant Non-Small Cell Lung Cancer (NSCLC)
09:45 - 09:45 | Presenter: Hayato Konno
- Abstract
Loading... -
+
P1.17-37 - Minimally Invasive Open Surgery (MIOS) for Clinical Stage I Lung Cancer: Perioperative Outcomes in Recent 5 Years
09:45 - 09:45 | Presenter: Kazuo Nakagawa
- Abstract
Loading... -
+
P1.17-38 - Does Use of Epidural Anesthesia Affects Survival of Resectable NSCLC? Analysis from a Japanese Nationwide Database (Now Available)
09:45 - 09:45 | Presenter: Kento James Fukumoto
- Abstract
Loading... -
+
P1.17-39 - Preoperative Prediction of Incomplete Resection in Non-Small Cell Lung Cancer: An Externally Validated Clinical Nomogram (Now Available)
09:45 - 09:45 | Presenter: Marnix Rasing
- Abstract
Loading... -
+
P1.17-40 - Clinical Implications of Using Circulating Tumor DNA to Assess Minimal Residual Disease (MRD) in Patients with NSCLC After Definitive Treatment
09:45 - 09:45 | Presenter: Nicholas I. Simon
- Abstract
Loading... -
+
P1.17-41 - Preoperative Prognostic Nutritional Index (PNI) as a Prognostic Factor in Patients with Clinical Stage I Non-Small-Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Mitsuyoshi Matsumoto
- Abstract
Loading... -
+
P1.17-42 - The Importance of Lymphatic and Vascular Invasion in Stage 1 Non-Small Cell Lung Cancer and Definition of a Totally Curable Tumors
09:45 - 09:45 | Presenter: Akif Turna
- Abstract
Loading... -
+
P1.17-43 - Sublober Resection for Adenocarcinoma in Situ Diagnosed by Intraoperative Frozen Sections
09:45 - 09:45 | Presenter: Toshiyuki Shima
- Abstract
Loading...
-
+
P1.18 - Treatment of Locoregional Disease - NSCLC
- Type: Poster Viewing in the Exhibit Hall
- Track: Treatment of Locoregional Disease - NSCLC
- Presentations: 14
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.18-01 - RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC (Now Available)
09:45 - 09:45 | Presenter: Santiago Ponce Aix
- Abstract
Loading... -
+
P1.18-02 - The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
09:45 - 09:45 | Presenter: John Victor Heymach
- Abstract
Loading... -
+
P1.18-03 - How to Predict High Grade Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Thoracic Radiotherapy (Now Available)
09:45 - 09:45 | Presenter: Jaume Bordas-Martinez
- Abstract
Loading... -
+
P1.18-04 - Neoadjuvant Ceritinib for Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: SAKULA Trial
09:45 - 09:45 | Presenter: Yoshitaka Zenke
- Abstract
Loading... -
+
P1.18-05 - ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy (Now Available)
09:45 - 09:45 | Presenter: Greg Durm
- Abstract
Loading... -
+
P1.18-06 - Efficacy and Safety of Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Non-Small Cell Lung Cancer
09:45 - 09:45 | Author(s): Ning Li
- Abstract
Loading... -
+
P1.18-07 - Postoperative Complications and Long-Term Survival Among Octogenarians Treated Surgically for Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Masanori Shimomura
- Abstract
Loading... -
+
P1.18-08 - Survival Outcomes of Salvage Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Sara Mieko Moore
- Abstract
Loading... -
+
P1.18-09 - Trimodal Treatment of Locally Advanced Non-Small Cell Lung Cancer: Model-Based Comparison with Chemoradiation Only (Now Available)
09:45 - 09:45 | Presenter: Malene Strange
- Abstract
Loading... -
+
P1.18-10 - The Prognostic Impact of the Extent of Nodal Involvement in NSCLC Treated with Radical Chemoradiation
09:45 - 09:45 | Presenter: Connie Yip
- Abstract
Loading... -
+
P1.18-11 - Dose Dense Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable/Borderline Resectable NSCLC - A Phase II Trial (Now Available)
09:45 - 09:45 | Presenter: Abhenil Mittal
- Abstract
Loading... -
+
P1.18-12 - PACIFIC-4/RTOG 3515: Phase III Study of Durvalumab Following SBRT for Unresected Stage I/II, Lymph-Node Negative NSCLC
09:45 - 09:45 | Author(s): Clifford Robinson
- Abstract
Loading... -
+
P1.18-13 - Predicting Failure Patterns in Patients with Inoperable Local Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy (Now Available)
09:45 - 09:45 | Presenter: Xueru Zhu
- Abstract
Loading... -
+
P1.18-14 - The Prognostic Significance of Significant Weight Loss in Stage III NSCLC Undergoing Definitive CRT After FDG-PET Staging (Now Available)
09:45 - 09:45 | Presenter: Clare Senko
- Abstract
Loading... -
+
P1.18-15 - Dosimetric and Toxicity Benefits of Adaptive IMRT in Patients with Stage III Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yinnan Meng
- Abstract
Loading... -
+
P1.18-16 - Is Tumor Shrinking During Chemoradiation for LA-NSCLC a Biomarker for Outcome? (Now Available)
09:45 - 09:45 | Presenter: Sara Ramella
- Abstract
Loading... -
+
P1.18-17 - Survival After Adjuvant Chemotherapy in Completely Resected N1 Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Emily Wang
- Abstract
Loading... -
+
P1.18-18 - Feasibility of Hypofractionated Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Noelle Caroline Van Der Voort Van Zyp
- Abstract
Loading... -
+
P1.18-19 - Invasive Mediastinal Staging Is Mandatory for Upfront Surgery for N2 Disease (Now Available)
09:45 - 09:45 | Presenter: Andrew Selvaraj
- Abstract
Loading... -
+
P1.18-20 - The Relationship Between the Recurrence Timing and Inflammation-Based Prognostic Scores in Resected Non-Small-Cell Lung Cancer
09:45 - 09:45 | Presenter: Daisuke Noma
- Abstract
Loading... -
+
P1.18-21 - Short and Mid-Term Outcomes of Multimodal Treatment for Locally-Advanced Non Small Cell Lung Cancer in Elderly Patients
09:45 - 09:45 | Author(s): stefano Bongiolatti
- Abstract
Loading... -
+
P1.18-22 - Impact of Using Volumetric Modulated Arc Therapy on Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Nobuki Imano
- Abstract
Loading... -
+
P1.18-23 - Use of Perfusion SPECT to Preserve Functional Lung in Radiotherapy for Non-Small-Cell Lung Cancer (NSCLC) Patients (Now Available)
09:45 - 09:45 | Presenter: Sara Ramella
- Abstract
Loading... -
+
P1.18-24 - Neoadjuvant Therapy versus Upfront Surgery for NSCLC Patients with Clinically Suspected Subaortic or Paraaortic Lymph Nodes
09:45 - 09:45 | Presenter: Junghee Lee
- Abstract
Loading... -
+
P1.18-25 - The Impact of Radiation Pneumonitis on Prognosis of Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy (Now Available)
09:45 - 09:45 | Presenter: Takahiro Akita
- Abstract
Loading... -
+
P1.18-26 - Pretreatment Risk Factors for Postoperative Pulmonary Complication After Neoadjuvant Concurrent Chemoradiotherapy for NSCLC
09:45 - 09:45 | Presenter: Woo Sik Yu
- Abstract
Loading... -
+
P1.18-27 - Chemoradiotherapy of Inoperable Non-Small Cell Lung Cancer (NSCLC) with IGRT Technique Using TomoTherapy HD
09:45 - 09:45 | Presenter: Milada Zemanova
- Abstract
Loading... -
+
P1.18-28 - Salvage Surgery for Residual Lesion/Local Reprogression After Initial Medical Treatment in Advanced Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Keita Nakanishi
- Abstract
Loading...
-
+
PR02 - Press Conference
- Type: Press Conference
- Track: Immuno-oncology
- Presentations: 4
- Now Available
- Coordinates: 9/08/2019, 09:45 - 10:30, CC7.1 A&B
-
+
PR02.01 - Summary of Day's Plenary
09:45 - 09:50 | Presenter: Enriqueta Felip
- Abstract
No abstract available for this presentation
-
+
PR02.02 - Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRAS G12C Inhibitor, Evaluated in NSCLC (Now Available)
09:50 - 09:57 | Presenter: Ramaswamy Govindan
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PR02.03 - Announcement of JTO Clinical and Research Reports
09:57 - 10:02 | Presenter: Alex A Adjei
- Abstract
No abstract available for this presentation
-
+
PR02.04 - Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial (Now Available)
10:02 - 10:09 | Presenter: Naiyer A Rizvi
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PR02.05 - CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC (Now Available)
10:09 - 10:16 | Presenter: Fabrice Barlesi
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PR02.06 - KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
10:16 - 10:23 | Presenter: Corey Jay Langer
- Abstract
No abstract available for this presentation
-
+
PR02.07 - Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC (Now Available)
10:23 - 10:30 | Presenter: Marina Chiara Garassino
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ES01 - What Is the Role of Chemotherapy in the Era of Immunotherapy in Advanced NSCLC?
- Type: Educational Session
- Track: Advanced NSCLC
- Presentations: 6
- Now Available
- Moderators:Oscar Gerardo Arrieta
- Coordinates: 9/08/2019, 10:30 - 12:00, Hilton Head (1978)
-
+
ES01.01 - Chemotherapy is Strictly Additive to Immunotherapy (Now Available)
10:30 - 10:45 | Presenter: Johan Vansteenkiste
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES01.02 - Chemotherapy Enhances the Efficacy of Immunotherapy (Now Available)
10:45 - 11:00 | Presenter: Natasha B Leighl
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES01.03 - Chemotherapy Directly Targets the Immune System to Improve Efficacy (Now Available)
11:00 - 11:15 | Presenter: Daniel SW Tan
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES01.04 - Immunotherapy, Radiotherapy and Chemotherapy Combination: A Potential New Standard? (Now Available)
11:15 - 11:30 | Presenter: Maurice Perol
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES01.05 - Future of Dual Anti-CTLA4 and PD1/PDL1 Blockade (Now Available)
11:30 - 11:45 | Presenter: David R Spigel
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES01.06 - Q&A (Now Available)
11:45 - 12:00
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ES02 - Management of Oncogene Addicted Patients with Stage III NSCLC
- Type: Educational Session
- Track: Treatment of Locoregional Disease - NSCLC
- Presentations: 5
- Now Available
- Moderators:Carlos Camps
- Coordinates: 9/08/2019, 10:30 - 12:00, Vancouver (2003)
-
+
ES02.01 - Biomarker Testing in LA Disease (Now Available)
10:30 - 10:45 | Presenter: Helena A Yu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES02.02 - Management of EGFR LA Disease (Now Available)
10:45 - 11:00 | Presenter: Keunchil Park
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES02.03 - Management of Other Non EGFR Oncogene Addicted Tumors (Now Available)
11:00 - 11:15 | Presenter: Charu Aggarwal
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES02.04 - Concurrent, Sequential and Combination Immunotherapy Regimens in LA-NSCLC (Now Available)
11:15 - 11:30 | Presenter: Mariano Provencio
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES02.05 - Q&A (Now Available)
11:30 - 12:00
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ES03 - BAP-1 and Other Novel Molecular and Metabolic Targets in Mesothelioma
- Type: Educational Session
- Track: Mesothelioma
- Presentations: 6
- Now Available
- Moderators:Michele Carbone
- Coordinates: 9/08/2019, 10:30 - 12:00, Tokyo (1982)
-
+
ES03.01 - Targeting Altered microRNA Expression in Mesothelioma (Now Available)
10:30 - 10:40 | Presenter: Glen Reid
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES03.02 - Targeting CDKN2A in Mesothelioma (Now Available)
10:40 - 10:50 | Presenter: Dean Anthony Fennell
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES03.03 - Targeting NF2 in Mesothelioma (Now Available)
10:50 - 11:00 | Presenter: Yoshitaka Sekido
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES03.04 - Pegargiminase to Treat Mesothelioma (Now Available)
11:00 - 11:10 | Presenter: Peter Szlosarek
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES03.05 - Inherited Predisposition to Mesothelioma, Biological and Clinical Differences with Sporadic Mesothelioma (Now Available)
11:10 - 11:20 | Presenter: Jane E. Churpek
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES03.06 - Q&A (Now Available)
11:20 - 12:00
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.